-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded during trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.
Wall Street Analyst Weigh In
Separately, Credit Suisse Group lowered their price objective on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.
Get Candel Therapeutics alerts:Candel Therapeutics Stock Down 5.3 %
The company has a debt-to-equity ratio of 0.34, a quick ratio of 14.86 and a current ratio of 14.86. The stock has a market capitalization of $92.74 million, a P/E ratio of -3.96 and a beta of 0.95. The stock's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $3.81.
Institutional Investors Weigh In On Candel Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Empirical Asset Management LLC bought a new stake in shares of Candel Therapeutics in the 1st quarter valued at $61,000. Kestra Advisory Services LLC bought a new stake in shares of Candel Therapeutics in the 1st quarter valued at $64,000. 683 Capital Management LLC bought a new stake in shares of Candel Therapeutics in the 4th quarter valued at $320,000. BlackRock Inc. boosted its stake in shares of Candel Therapeutics by 15.5% in the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company's stock valued at $674,000 after purchasing an additional 17,708 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Candel Therapeutics in the 2nd quarter valued at $2,408,000. 21.97% of the stock is owned by institutional investors.Candel Therapeutics Company Profile
(Get Rating)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Featured Articles
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded during trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.
坎德尔治疗公司(纳斯达克代码:CADL-GET评级)的股价在周三午盘交易中下跌5.3%。该公司股价低至3.20美元,最新报3.21美元。当日成交量为6,148股,较33,482股的平均日成交量下降82%。该股此前收盘价为3.39美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, Credit Suisse Group lowered their price objective on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.
另外,瑞士信贷集团在8月15日星期一的一份研究报告中将Candel治疗公司的股票目标价下调至11.00美元。
Candel Therapeutics Stock Down 5.3 %
Candel治疗公司股价下跌5.3%
The company has a debt-to-equity ratio of 0.34, a quick ratio of 14.86 and a current ratio of 14.86. The stock has a market capitalization of $92.74 million, a P/E ratio of -3.96 and a beta of 0.95. The stock's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $3.81.
该公司的负债权益比率为0.34,速动比率为14.86,流动比率为14.86。该股市值为9,274万美元,市盈率为-3.96,贝塔系数为0.95。该股的50日简单移动均线为3.41美元,200日简单移动均线为3.81美元。
Institutional Investors Weigh In On Candel Therapeutics
机构投资者看好Candel治疗公司
Candel Therapeutics Company Profile
坎德尔治疗公司简介
(Get Rating)
(获取评级)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Candel Treateutics,Inc.是一家临床阶段的生物制药公司,致力于为癌症患者开发免疫疗法。该公司开发了CAN-2409,这是治疗胰腺癌的第二阶段临床试验;治疗前列腺癌的第三阶段临床试验;以及治疗肺癌的第二阶段临床试验,以及治疗高级别胶质瘤的Ib/II阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免费获取StockNews.com关于Candel治疗(CADL)的研究报告
- 对塔吉特来说,最糟糕的时期可能已经过去,但这只股票买起来安全吗?
- 这些液态天然气股票准备好上行了吗?
- 内部人士正在买入的两只有趣的股票
- 诺华在避险市场中仍是一只冒险的股票
- 连续60年提高股息的3只防御性股票
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《秋茄治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Candel Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧